Biovica International AB is engages in the development and commercialization of novel blood-based biomarker assays to improve the monitoring of modern cancer therapies. The company is headquartered in Uppsala, Uppsala and currently employs 27 full-time employees. The company went IPO on 2017-03-29. The company develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The firm has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The firm collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.

Frequently Asked Questions